Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Announces Expedited Individual Genome Sequencing Service

Published: Friday, February 01, 2013
Last Updated: Friday, February 01, 2013
Bookmark and Share
Breakthrough turnaround time for human genome sequencing available via Illumina’s CLIA-certified laboratory.

Illumina, Inc. has announced the introduction of its rapid Individual Genome Sequencing (IGS) service with a turnaround time in as little as two weeks.

Rapid turnaround whole genome sequencing services were announced by Illumina in June 2012, enabled by technology innovations to the HiSeq® platform.

Now these advancements have been implemented in Illumina’s CLIA-certified laboratory to enable the same fast turnaround for the IGS service.

The IGS service is only available through a physician’s order and is designed to assist clinicians with diagnosis and treatment decisions.

As the only CLIA-certified, CAP-accredited whole genome sequencing service laboratory in the world, Illumina continues to increase access and lay the foundation for routine clinical use of whole-genome sequencing.

“Illumina has long believed that sequencing will become a mainstream practice in the clinical setting. By delivering a whole human genome in as little as two weeks, we have taken significant strides towards that goal,” said Illumina President and CEO Jay Flatley.

Flatley continued, “Whole genome sequencing is quickly gaining recognition for its potential in diagnostics and treatment decisions, particularly in cases where physicians are challenged with identifying a disorder based on symptoms that don't quite fit with a known disease. When this happens, rapid whole-genome sequencing can provide big-picture information about genetic makeup, enabling physicians to make more informed decisions and patients to obtain answers more quickly.”

Validated for laboratory use in accordance with CLIA and CAP regulations and guidelines, Illumina’s fast IGS service uses Illumina’s HiSeq 2500® sequencing system, which is capable of completing a sequencing run on a whole human genome in one day.

The service will continue to deliver the highest quality, most comprehensive data with the broadest coverage of exomic, promoter, and regulatory regions, as well as fully annotated variants to facilitate clinical interpretation, now available faster.

Illumina is also working on a suite of analytic tools and professional services in collaboration with physicians and medical geneticists to improve clinical interpretation.

“Illumina has delivered on the promise of personalized healthcare by not only enabling clinical interrogation of the whole genome, but also providing the results in a turnaround time consistent with the demands of patient care. This is a game-changer that will revolutionize our field,” said Dr. Leonard Sender, Medical Director, CHOC Hyundai Cancer Institute and Director of the Young Adult Cancer Program at the University of California, Irvine Chao Family Comprehensive Cancer Center.

Initially, the rapid turnaround option is available with limited capacity, and cases will be prioritized by severity in consultation with ordering physicians.

Later this year, Illumina will begin offering focused clinical interpretation for CLIA services, working closely with ordering physicians and leveraging bioinformatics tools and internal medical genetics expertise.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Accelerator Welcomes First International Fellow
Illumina Accelerator has expanded their startup pool with the Center of Individualized Diagnostics (CID).
Wednesday, August 24, 2016
Illumina Applauds FDA’s Issuance of Draft Guidances
Company has supported the FDA in their efforts to provide a flexible and streamlined approach to the oversight of NGS diagnostic test.
Friday, July 08, 2016
Illumina Announces Agricultural Greater Good Initiative Grant
The grant program is designed to help identify measures that can increase crop yields and improve livestock welfare and productivity to alleviate poverty and hunger in the developing world.
Tuesday, June 14, 2016
ArcherDX, Illumina Launch Collaboration
Agreement to bring multiple Archer® assays through the FDA approval process.
Tuesday, May 31, 2016
Illumina Registers MiSeqDx System in South Korea
Regulatory milestone clears path for clinical laboratories to use Illumina NGS technology.
Tuesday, May 10, 2016
Illumina Files Patent Infringement Suit against Genoma SA
Company has announced that it has filed a patent infringement suit against Genoma SA in the Switzerland for Infringement of NIPT Patents.
Friday, April 22, 2016
Illumina Invests In New Venture Fund
Illumina will commit $100M over 10 years to drive genomic technology development.
Friday, April 15, 2016
Illumina Applies CE Mark to VeriSeq™ NIPT Analysis Software
Company has announced that it has applied the CE mark to expand the use of VeriSeq NIPT analysis software in clinical laboratories.
Thursday, February 25, 2016
Illumina Sues Oxford Nanopore for Patent Infringement
Illumina, Inc. has announced that the company filed lawsuits against Oxford Nanopore Technologies Ltd. and Oxford Nanopore Technologies, Inc. (ONT).
Wednesday, February 24, 2016
Genomics England, Illumina Enter Bioinformatics Partnership
Illumina, and Genomics England have announced a partnership to develop a platform and knowledge base that can be used to improve and automate genome interpretation.
Thursday, February 11, 2016
Illumina Signs Multiple Biobank Deals
Company has signed four deals to advance personalized medicine and improve health care.
Tuesday, February 09, 2016
Illumina Signs Multiple Biobank Deals
MEGA array family and next-generation sequencing to support comprehensive genomics approach toward personalized medicine.
Wednesday, February 03, 2016
Illumina Appoints Dr. Frances Arnold to its Board of Directors
Dr. Arnold is the Director of the Donna and Benjamin M. Rosen Bioengineering Center.
Sunday, January 31, 2016
Illumina Appoints Dr. Frances Arnold to Its Board of Directors
Illumina, Inc. has announced that Dr. Frances Arnold has joined the company’s Board of Directors. Dr. Arnold manages a research group at the California Institute of Technology and is the Director of the Donna and Benjamin M. Rosen Bioengineering Center.
Thursday, January 28, 2016
Illumina Acquires Conexio Genomics
Acquisition strengthens company’s ability to deliver sample-to-report solutions for HLA typing.
Wednesday, January 27, 2016
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
“Sixth Sense” May Be More Than Just A Feeling
The NIH Study shows that two young patients with a mutation in the PIEZ02 have problems with touch and proprioception, or body awareness.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!